Shenzhen MingSight Relin Pharmaceuticals

Privately held: no public share price · China

Assets

(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
2Diseases
Quick filter:
Showing 1 of 1 assets
Target & Modality
Phase 1/2
Protein kinase C-beta (PKC-beta)Small molecule
Diabetic Macular EdemaChronic Lymphocytic Leukemia

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2028 (1)
September 2028 (1)
MS-553Phase 1/2CLL (Chronic Lymphocytic Leukemia), SLL (Small Lymphocytic Lymphoma)
Est. primary completion 2028-09 · NCT06979076 · CT.gov ↗
What to watch

See the full readout calendar ↗

Financial reports

No financial reports recorded.